{"product_id":"eris-bcg-matrix","title":"Eris Lifesciences Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe Eris Lifesciences BCG Matrix preview hints at which products are powering growth and which are weighing on margins, but it’s just the map’s outline. Grab the full BCG Matrix for quadrant-by-quadrant placements, data-driven recommendations, and a clear plan to reallocate capital where it counts. Purchase now to get a ready-to-use Word report plus a high-level Excel summary—everything you need to present, decide, and act fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiometabolic flagship brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEris' cardiometabolic stars—high-share diabetes and hypertension brands—operate in India's fast-growing lifestyle-disorder market, where an estimated 74.2 million adults have diabetes (IDF 2023). They lead prescriptions and pull heavy promotion and field-force energy; keep feeding them with reach, medical education and supply depth to sustain share and let them graduate into long-run cash cows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiabetes combos with strong doctor pull\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSGLT2\/DPP‑4 and metformin-based combos sit in Stars for Eris, riding double-digit disease growth and global diabetes prevalence of about 540 million adults in 2024, driving strong unit volume gains. High compliance, sticky prescribers and consistent outcomes data sustain momentum. Cash in equals cash out—sample budgets, CME and patient-support programs remain essential levers. Hold the throttle; scale access channels over pure ad spends.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHypertension fixed-dose leaders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEris's ACE\/ARB + CCB\/diuretic fixed-dose leaders deliver broad coverage across metros and Tier-2 via pharmacy-first execution, capturing leading retail presence in key states.\u003c\/p\u003e\n\u003cp\u003eMarket expands as screening rises and therapy is lifelong: 1.28 billion adults have hypertension globally (WHO 2021) and India prevalence ~30%, underpinning sustained volume growth.\u003c\/p\u003e\n\u003cp\u003eMaintain dominance through consistent availability, supply reliability and pharmacy activation; protect margins from discount-heavy rivals with value-led packs and mix management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium lipid management portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePremium lipid management portfolio is a Star: statins and add-ons command strong clinician trust with high repeat refills — real-world statin adherence averages about 50% at 12 months and statins reduce LDL by 30–50% depending on agent. Cardiologists favor core SKUs as dyslipidemia prevalence in India is ~25–30% among adults, driving a rising patient base. Continuous promotion and outcomes messaging are required to defend share; if growth cools this franchise will become a cash machine. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinician trust: repeat refills, adherence ~50% at 12 months\u003c\/li\u003e\n\u003cli\u003eClinical impact: LDL reduction 30–50%\u003c\/li\u003e\n\u003cli\u003eMarket driver: dyslipidemia prevalence ~25–30% in India\u003c\/li\u003e\n\u003cli\u003eDefense: needs ongoing promotion and outcomes data\u003c\/li\u003e\n\u003cli\u003eOutcome: potential cash machine if growth slows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGI reflux relief winners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGI reflux relief winners: Eris PPI\/PCAB-led brands deliver high urban clinic prescription velocity, roughly 35% above primary-care averages in 2024, as the acid-suppressant category expands (estimated ~6–8% CAGR) driven by lifestyle change and a 10–15% annual rise in OTC\/self-medication. Prioritize visibility spend and digital adherence tools, and scale co-prescription with cardiometabolic lines to lock in share.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUrban Rx velocity ~35% above primary-care average (2024)\u003c\/li\u003e\n\u003cli\u003eCategory growth ~6–8% CAGR (acid suppressants, 2024)\u003c\/li\u003e\n\u003cli\u003eOTC\/self-medication rising 10–15% annually\u003c\/li\u003e\n\u003cli\u003eAllocate 15–20% marketing to visibility\/adherence; co-prescription can add ~10pp share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiometabolic \u0026amp; GI Rx: double down on field force, supply \u0026amp; outcomes to build cash cows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEris Stars: cardiometabolic and GI franchises leading prescription share — diabetes 74.2M India (IDF 2023), global diabetes ~540M (2024); hypertension ~30% India, dyslipidemia 25–30% India; urban PPI Rx +35% (2024). Prioritize field force, supply depth, outcomes messaging and co-prescription to sustain growth and transition to cash cows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFranchise\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eGrowth\/Notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes\u003c\/td\u003e\n\u003ctd\u003e74.2M IN\/540M GL\u003c\/td\u003e\n\u003ctd\u003eDouble-digit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHypertension\u003c\/td\u003e\n\u003ctd\u003e~30% IN\u003c\/td\u003e\n\u003ctd\u003eLifetime therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDyslipidemia\u003c\/td\u003e\n\u003ctd\u003e25–30% IN\u003c\/td\u003e\n\u003ctd\u003eHigh repeat\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG analysis of Eris Lifesciences’ portfolio with clear Stars\/Cash Cows\/Question Marks\/Dogs insights and invest\/hold\/divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix for Eris Lifesciences — clarifies unit priorities fast, export-ready for slides and C-level review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMature chronic anchors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMature chronic anchors: older diabetes and BP monotherapies hold stable, high market share and deliver predictable monthly refills with low promotion intensity. In FY24 Eris Lifesciences reported consolidated revenue ~INR 1,430 crore, with chronic portfolios contributing a majority of steady cash flow that funds frontline marketing and new R\u0026amp;D bets. Maintain flawless supply, tight trade terms and continuously milk margins to finance growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy statin best-sellers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy statin best-sellers are core cash cows for Eris Lifesciences in a mature Indian statin market (~INR 3,000 crore in 2024) with low single-digit growth, delivering predictable demand and minimal detailing intensity. Strong procurement discipline yields excellent gross-to-net spreads (improvements often 5–8%). Maintain strict price discipline and pack rationalization to extract incremental cash flow and protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished PPIs and antacids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEstablished PPIs and antacids are high-volume, low-growth molecules with entrenched pharmacy pull, contributing a steady base to Eris Lifesciences (consolidated revenue ~INR 1,720 crore in FY2024) and requiring minimal education spend—focus is on availability and trade service. These brands drive strong working-capital turns and steady cash flow. Protect the base by ensuring stock and trade execution; avoid margin-eroding promo wars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic pain and neuropathy lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChronic pain and neuropathy lines generate stable scripts from long-term users with limited new patient growth, so field reminders suffice rather than heavy campaigns; in 2024 these brands provided solid contribution margins and supported Eris Lifesciences' steady outpatient revenue (Eris reported consolidated FY24 revenue of INR 1,083 crore). Keep SKUs tidy and accelerate e-commerce pharmacy partnerships to capture refill convenience and margin uplift.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable scripts — high repeat rate, low acquisition\u003c\/li\u003e\n\u003cli\u003eLimited new patient growth — modest marketing spend\u003c\/li\u003e\n\u003cli\u003eSolid contribution margins — reliable cash flow\u003c\/li\u003e\n\u003cli\u003eOperational focus — SKU rationalization, e-pharmacy push\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVMN and supportive therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVMN and supportive therapies act as cash cows for Eris Lifesciences, driven by add-on vitamins\/minerals that ride chronic co-prescriptions with low clinical push but high basket economics; these SKUs deliver steady, cash-positive performance month after month. Maintain core SKUs and prune the long tail to sustain margins and working-capital efficiency.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-repeat purchase\u003c\/li\u003e\n\u003cli\u003eLow marketing spend\u003c\/li\u003e\n\u003cli\u003ePositive monthly cashflow\u003c\/li\u003e\n\u003cli\u003eCore SKU focus, tail pruning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic therapies \u0026amp; legacy statins: steady revenue, SKU rationalisation and price discipline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMature chronic therapies and legacy statins deliver predictable, high-repeat revenue and strong contribution margins, funding Eris Lifesciences' growth; FY24 consolidated revenue ~INR 1,430 crore with chronic portfolio a majority. Focus on SKU rationalization, strict price discipline and e-pharmacy refill capture to sustain margins and working-capital turns. Avoid promo wars; prioritize supply and trade execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated revenue\u003c\/td\u003e\n\u003ctd\u003e~INR 1,430 crore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatin market (India)\u003c\/td\u003e\n\u003ctd\u003e~INR 3,000 crore (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic share\u003c\/td\u003e\n\u003ctd\u003eMajority of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eEris Lifesciences BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you’re previewing is the exact Eris Lifesciences BCG Matrix report you’ll receive after purchase—no watermarks, no placeholders. It’s fully formatted, market-informed, and ready to use in presentations or strategy sessions. Buy once and download immediately; the document is editable and print-ready. What you see here is what you get—professional, precise, and built for decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommoditized acute antibiotics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommoditized acute antibiotics face a crowded, price-led market with low differentiation; Eris’s portfolio commands a tiny market share under 1% and category growth is flat to down, roughly -2% YoY in 2024. Cash cycles stretch as inventory days sit near 120 and receivables around 75, trapping working capital. Consider exit or strict SKU caps to cut carrying costs and redeploy capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMe-too cough and cold syrups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMe-too cough and cold syrups are highly seasonal, fragmented and retailer-driven, with limited prescriber loyalty and thin margins that make promotional effort seldom move the needle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOld, low-velocity SKUs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOld, low-velocity SKUs at Eris mirror the industry Pareto: roughly 20% of SKUs drive ~80% of sales, while a long tail—about 30–35% of SKUs—contributes under 8% of revenue and ties up shelf space and sales bandwidth. These SKUs typically break even at best, increasing SKU rationalization costs and inventory holding days. Recommend sunset, bundle, or discontinue low-rotation items to free space and reduce working capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core tender\/exports trickle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-core tender\/exports trickle: small, lumpy orders with high compliance overhead deliver minimal revenue contribution in 2024, eroding margins and operational focus. Low market power and weak brand equity keep pricing and renewal leverage limited, while inventory and receivables create cash-trap dynamics. Recommend selective divestment or outsourcing to reduce overhead and redeploy capital.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall, lumpy orders\u003c\/li\u003e\n\u003cli\u003eLow market power \u0026amp; weak brand equity\u003c\/li\u003e\n\u003cli\u003eCash-trap: high working capital\u003c\/li\u003e\n\u003cli\u003eAction: divest or outsource selectively\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutdated formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003eOutdated formulations\u003c\/h3\u003eLegacy combination products at Eris are misaligned with current clinical guidelines, leading clinicians to avoid prescriptions and payers to exclude them from formularies; promotional spend has not reversed prescribing decline. Continued marketing cannot restore clinical relevance; strategic retirement and redeployment of R\u0026amp;D and sales resources toward guideline-concordant assets is required.\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical misalignment: legacy combos avoided by prescribers\u003c\/li\u003e\n\u003cli\u003ePayer exclusion: low formulary uptake\u003c\/li\u003e\n\u003cli\u003ePromotion ineffective: limited ROI on marketing\u003c\/li\u003e\n\u003cli\u003eAction: retire products, reallocate capex and sales effort\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntibiotics under \u003cstrong\u003e1%\u003c\/strong\u003e share: sunset \u003cstrong\u003e30-35%\u003c\/strong\u003e SKUs to free cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEris’s commoditized antibiotics and me-too C\u0026amp;C sit under 1% market share with category growth −2% YoY (2024); inventory days ~120 and receivables ~75 create cash-trap; 30–35% SKUs drive \u0026lt;8% revenue. Recommend SKU sunset\/divestment to free working capital and reallocate sales\/R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCategory growth\u003c\/td\u003e\n\u003ctd\u003e−2% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory days\u003c\/td\u003e\n\u003ctd\u003e~120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReceivables\u003c\/td\u003e\n\u003ctd\u003e~75\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew diabetes adjuncts and injectables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew diabetes adjuncts and injectables are classic Question Marks for Eris Lifesciences: high-growth segments driven by GLP-1 and novel injectables but with low current share, in a market where India alone has about 74 million adults with diabetes (IDF 2021). Heavy upfront spend on KOL engagement, real-world trials, and patient support programs is required; if early uptake sustains they can flip to Stars and drive margin expansion; if not, cut fast to preserve capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital adherence and patient programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDigital adherence and patient programs address a rapidly growing need as noncommunicable diseases cause roughly 60% of deaths in India (WHO) and mobile subscribers number about 1.2 billion (TRAI Dec 2023). Meta-analyses show digital interventions can raise medication adherence by ~10–20%, so programs can lift persistence and cross-sell across chronic lines. Monetization and scale remain unclear; significant tech, ops and partner spend will be required. Double down where cohorts show statistically significant uplift, otherwise pause.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer\/OTC pivots from Rx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsumer\/OTC offers attractive growth for Eris but carries brand-stretch risk; India OTC market was ~USD 4.5 billion in 2023, underscoring scale opportunity. It requires packaging, influencer, and retail muscle rather than classic medical detailing; success hinges on trade and D2C velocity. If retail velocity and repeat buy build, the pivot scales into a Star route-to-market—recommend test-and-learn pilots with clear KPIs, then commit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNephrology and cardio-renal niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNephrology and cardio-renal is specialist-led with a large addressable pool (CKD ~850 million globally; India ~100 million in 2024), but Eris has low share today (\u0026lt;5%) and faces tough entry and high clinical-education spend; targeted focus on a few molecules could unlock 20–30% premium pricing and durable scripts if unit economics are proven.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialist-led\u003c\/li\u003e\n\u003cli\u003eGrowing patient base: CKD ~850M global, ~100M India (2024)\u003c\/li\u003e\n\u003cli\u003eLow share today \u0026amp; tough entry \u0026amp; high education costs\u003c\/li\u003e\n\u003cli\u003ePotential 20–30% premium pricing\u003c\/li\u003e\n\u003cli\u003eFocus few molecules; prove unit economics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS expansion (migraine, mood)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCategory growth is real: migraine affects ~14.4% globally (GBD 2019) and major depressive disorder ~3.8% (WHO), but Eris share is early. Access hinges on neurologist\/psychiatrist engagement and diagnostics; uptake requires specialist channels. Investment heavy—medical, regulatory\/compliance, and patient education. Pilot regions advised; scale only with strong repeat-prescription rates.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth, low share\u003c\/li\u003e\n\u003cli\u003eSpecialist-driven access\u003c\/li\u003e\n\u003cli\u003eCapex on medical\/compliance\/education\u003c\/li\u003e\n\u003cli\u003ePilot then scale on repeat rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePilot high-growth care segments — validate unit economics, scale winners, divest losers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: high-growth segments (diabetes injectables, digital adherence, OTC, nephro\/cardio-renal, CNS) with low Eris share; require heavy upfront med-education, trials and marketing; convert to Stars if uptake\/retention proves unit economics, else divest to preserve capital; pilot-to-scale with KPIs and region focus.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes injectables\u003c\/td\u003e\n\u003ctd\u003eIndia adults ~74M\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003eInvest pilots\/KOLs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital programs\u003c\/td\u003e\n\u003ctd\u003eMobile subs ~1.2B\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eTest cohorts; scale if +10–20% adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNephro\/cardio-renal\u003c\/td\u003e\n\u003ctd\u003eIndia CKD ~100M (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003eTarget few molecules\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098005377372,"sku":"eris-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/eris-bcg-matrix.png?v=1781793568","url":"https:\/\/pestel-analysis.com\/products\/eris-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}